Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 30;12(6):1355-1357.
doi: 10.21037/tlcr-23-115. Epub 2023 Mar 20.

Tarlatamab: the promising immunotherapy on its way from the lab to the clinic

Daolin Tang  1 , Rui Kang  1
Affiliations
Editorial

Tarlatamab: the promising immunotherapy on its way from the lab to the clinic

Daolin Tang et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Tarlatamab; bispecific T cell engager (BiTE); immunotherapy; lung cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-115/coif). Research by DT and RK was supported by grants from the National Institutes of Health (Nos. R01CA160417, R01CA229275, and R01CA211070).

Figures

Figure 1
Figure 1
Mechanism of tarlatamab-mediated tumor suppression in SCLC. Tarlatamab, also known as AMG 757, is a BiTE. By binding to DLL3 on tumor cells and CD3 on T cells, tarlatamab enables the recruitment and activation of T cells, which in turn leads to the destruction of tumor cells. This mechanism of action makes tarlatamab a promising therapeutic option for the treatment of SCLC. CD3, cluster of differentiation 3; DLL3, delta-like ligand 3; SCLC, small cell lung cancer; BiTE, bispecific T cell engager.
See this image and copyright information in PMC

Comment on

References

    1. Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers 2021;7:3. 10.1038/s41572-020-00235-0 - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33. 10.3322/caac.21708 - DOI - PubMed
    1. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 2017;17:725-37. 10.1038/nrc.2017.87 - DOI - PubMed
    1. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018;379:2220-9. 10.1056/NEJMoa1809064 - DOI - PubMed
    1. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:1929-39. 10.1016/S0140-6736(19)32222-6 - DOI - PubMed